Pfizer is in talks with India to provide avid vaccines

Pfizer is in talks with India and has decided to make its COVID-19 vaccine available for development in the country, Reuters quoted the US drug dealer as saying. The company said it offered India a non-profit price for its vaccine for the government’s immunization program.

Last week the Indian government said it would speed up emergency approvals for foreign vaccines COVID-19, a move that would exempt companies from doing “cross-cutting” tests for their vaccines.

Meanwhile, Johnson & Johnson said it is trying to do a local clinical trial in India for its single-dose COVID-19 vaccine.

India is struggling with a massive increase in avid cases, which has severely strained its health system and caused a shortage of oxygen and medicines.

India today recorded the world’s highest daily count of 314,835 COVID-19 infections in one day.

According to Reuters, the previous record one-day increase in cases was held by the United States, which had 297,430 new cases in one day in January, although its count has since fallen sharply.

India’s total cases are now 15.93 million, while deaths have risen by 2,104 in the past 24 hours to reach a total of 184,657, according to the latest health ministry data.

The Indian government will open its vaccination on May 1 to cover those over 18 years of age.

This week Prime Minister Narendra Modi urged state governments to use locks as a last resort. He asked people to stay indoors and said the government is working to increase the supply of oxygen and vaccines.

Meanwhile, Pfizer has announced that it will deliver an additional 100 million doses of its COVID-19 vaccine to the 27 member states of the European Union (EU) in 2021. This announcement is a result of the European Commission’s decision to implement its choice. to purchase an additional 100 million doses in accordance with its expanded Advanced Purchase Agreement signed on 17 February 2021. This brings the total number of doses to be delivered to the EU to 600 million.

Subscribe to Information Newsletters

* Please enter a valid email address

* Thank you for subscribing to our newsletter.

Source